Approval · Notice of Compliance 13812 · 2012
LUPRON: Notice of Compliance 13812
Issued November 2, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13812
- Date
- November 2, 2012
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Gonadotropin-releasing hormone analogue
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUPRON | 00727695 | Cancelled Post Market |
| LUPRON DEPOT | 00836273 | Marketed |
| LUPRON DEPOT | 00884502 | Marketed |
| LUPRON DEPOT | 02148722 | Cancelled Pre Market |
| LUPRON DEPOT | 02148730 | Cancelled Pre Market |
| LUPRON DEPOT | 02239833 | Marketed |
| LUPRON DEPOT (3 MONTH SLOW RELEASE) | 02230248 | Marketed |
| LUPRON DEPOT (3 MONTH SLOW RELEASE) | 02239834 | Marketed |
Medicinal ingredients
- LEUPROLIDE ACETATE 5 MG per ML
- LEUPROLIDE ACETATE 7.5 MG per VIAL
- LEUPROLIDE ACETATE 3.75 MG per VIAL
- LEUPROLIDE ACETATE 11.25 MG per VIAL
- LEUPROLIDE ACETATE 15 MG per VIAL
- LEUPROLIDE ACETATE 30 MG per VIAL
- LEUPROLIDE ACETATE 22.5 MG per VIAL